Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations
Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB)
treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB …
treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB …
Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study
S Wasserman, JCM Brust… - Journal of …, 2022 - academic.oup.com
Background Linezolid is recommended for treating drug-resistant TB. Adverse events are a
concern to prescribers but have not been systematically studied at the standard dose, and …
concern to prescribers but have not been systematically studied at the standard dose, and …
Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States
S Mase, T Chorba, S Parks, A Belanger… - Clinical Infectious …, 2020 - academic.oup.com
Abstract Background In 2012, the Food and Drug Administration approved use of
bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis …
bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis …
Population pharmacokinetics of linezolid in tuberculosis patients: dosing regimen simulation and target attainment analysis
The prolonged treatment duration for multidrug-resistant tuberculosis (MDR-TB) makes
linezolid dosing difficult because of adverse effects associated with long-term use. We …
linezolid dosing difficult because of adverse effects associated with long-term use. We …
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
GB Gomez, M Siapka, F Conradie, N Ndjeka… - BMJ open, 2021 - bmjopen.bmj.com
Objectives Patients with highly resistant tuberculosis have few treatment options.
Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have …
Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have …
[HTML][HTML] Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis
L Fu, T Weng, F Sun, P Zhang, H Li, Y Li, Q Yang… - International Journal of …, 2021 - Elsevier
Background Multidrug-resistant tuberculosis (MDR-TB) patients have been suffering long,
ineffective, and toxic treatment until short-course injectable-free regimens emerged …
ineffective, and toxic treatment until short-course injectable-free regimens emerged …
[HTML][HTML] Bedaquiline: A novel diarylquinoline for multidrug-resistant pulmonary tuberculosis
AT Deshkar, PA Shirure - Cureus, 2022 - ncbi.nlm.nih.gov
A new drug Bedaquiline, a diarylquinoline agent has been approved by the Food and Drug
Administration for the treatment of pulmonary multidrug-resistant tuberculosis. It has been …
Administration for the treatment of pulmonary multidrug-resistant tuberculosis. It has been …
[HTML][HTML] Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study
Background Rifampicin-resistant tuberculosis (RR-TB) is largely underdetected in
Indonesia. Xpert MTB/RIF (Xpert) has recently been introduced, prioritizing patients at risk of …
Indonesia. Xpert MTB/RIF (Xpert) has recently been introduced, prioritizing patients at risk of …
[HTML][HTML] Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational …
AJ Garcia-Prats, HS Schaaf, HR Draper… - PLoS …, 2019 - journals.plos.org
Background Linezolid is increasingly important for multidrug-resistant tuberculosis (MDR-
TB) treatment. However, among children with MDR-TB, there are no linezolid …
TB) treatment. However, among children with MDR-TB, there are no linezolid …
[HTML][HTML] Machine learning and radiomics for the prediction of multidrug resistance in cavitary pulmonary tuberculosis: a multicentre study
Y Li, B Wang, L Wen, H Li, F He, J Wu, S Gao… - European Radiology, 2023 - Springer
Objectives Multidrug-resistant tuberculosis (MDR-TB) is a major challenge to global health
security. Early identification of MDR-TB patients increases the likelihood of treatment …
security. Early identification of MDR-TB patients increases the likelihood of treatment …